Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England

“…Overall, the baseline characteristics were generally consistent with other real-world studies of cabozantinib use in RCC [ 28 , 33 , 34 , 37 , 39 , 44 , 45 ], and key clinical and demographic characteristics were broadly balanced between treatment cohorts. Some relevant data, however, were incompletely recorded in the CAS database, limiting the ability to characterize the population in terms of, for example, time from aRCC diagnosis to SACT initiation, other IMDC risk factors, ECOG PS scores, and prior nephrectomy status.…”

“…This study responded to a need for real-world data on commonly prescribed TKIs for patients with aRCC in England [ 39 ]. It described treatment patterns and outcomes for patients receiving ≥ 2L cabozantinib or axitinib following prior VEGF-targeted SACT between January 2011 and January 2020.…”

“…Several real-world studies have examined TKI use following other SACTs such as checkpoint inhibitors [ 27 – 37 ], but data specific to the real-world use of cabozantinib and axitinib after VEGF-targeted therapy in England remain limited [ 38 , 39 ]. We therefore conducted a retrospective observational cohort study of patients receiving ≥ second-line (2L) cabozantinib or axitinib following prior VEGF-targeted therapy for aRCC in routine care in England.…”

Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients—Real-World Experience in a Single-Center Retrospective Study and Narrative Review

“…These results were consistent with many real-world retrospective studies such as CERES, in which the ranges of OS and PFS were 6.01 and 10.84 months, respectively. Nevertheless, the median PFS in the CERES study was shorter, which can be explained by the fact that 99% of patients were treated at stage IV [ 47 ]. Median PFS for patients treated with cabozantinib in the Polish Managed Access Program (MAP) and Italian MAP were 12.5 months and 8 months, respectively [ 15 , 30 ].…”

“…The search yielded 222 papers, but only 51 of them were considered consistent with the topic of this paper were retrieved from PubMed. Then, we analyzed in detail and finally included information from 27 [ 15 , 18 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 ] publications that were considered useful for this manuscript, while the remaining references came from the personal knowledge of the authors [ 49 , 50 ]. In the end, we qualified 13 [ 15 , 26 , 27 , 28 , 29 , 31 , 33 , 34 , 35 , 42 , 44 , 51 , 52 ] works to formulate a table describing AEs; in the remaining 14 papers, information about AEs was insufficient.…”